Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Philina Lee Insider Profile
4 Followers
Philina Lee, Director at Fusion Pharmaceuticals, holds ― shares in Fusion Pharmaceuticals (Ticker: FUSN), holds 34.73K shares in Blueprint Medicines (Ticker: BPMC). Most recently, Philina Lee ― shares of Fusion Pharmaceuticals on ― for an estimated value of ―.
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-49.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
CCO
Roles that Philina Lee holds in companies
Most Profitable Insider Trade
The most profitable trade made by Philina Lee
Philina Lee's Trading History
Fusion Pharmaceuticals
―
―
―
―
Blueprint Medicines
Mar 15, 2024
CCO
Uninformative Buy
22.97K
$3.74M
List of latest transactions for each holding click on a transaction to see Philina Lee's performance on stock
You May Also Like
Philina Lee insider profile FAQ
What is the percentage of profitable transactions made by Philina Lee?
The percentage of profitable transactions made by Philina Lee is 0%.
What is the average return per transaction made by Philina Lee?
The average return per transaction made by Philina Lee is -49.80%.
What stocks does Philina Lee hold?
Philina Lee holds: FUSN, BPMC stocks.
What was Philina Lee’s latest transaction?
Philina Lee latest transaction was an Uninformative Buy of ―.
What was Philina Lee's most profitable transaction?
Philina Lee’s most profitable transaction was an Informative Sell of BPMC stock on March 15, 2024. The return on the trade was -19.00%.
What is Philina Lee's role in Fusion Pharmaceuticals?
Philina Lee's role in Fusion Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.